B7-H3 role in the immune landscape of cancer.
- 15 June 2017
- journal article
- review article
- Vol. 6 (4), 66-75
Abstract
The field of immunotherapy is a continually expanding niche in cancer biology research. In the last two decades, there has been significant progress in identifying better targets and creating more specific agents for therapy in the field. B7-H3 (CD276) is an immune checkpoint from the B7 family of molecules, many of whom interact with known checkpoint markers including CTLA4, PD-1, and CD28. This is an exciting molecule that is overexpressed in many cancers, although the receptor of B7-H3 has not been characterized. Initially, B7-H3 was thought to co-stimulate the immune response, but recent studies have shown that it has a co-inhibitory role on T-cells, contributing to tumor cell immune evasion. Therefore, its overexpression has been linked to poor prognosis in human patients and to invasive and metastatic potential of tumors in in vitro models. Moreover, recent evidence has shown that B7-H3 influences cancer progression beyond the immune regulatory roles. In this review, we aim to characterize the roles of B7-H3 in different cancers, its relationship with other immune checkpoints, and its non-immunological function in cancer progression. Targeting B7-H3 in cancer treatment can reduce cell proliferation, progression, and metastasis, which may ultimately lead to improved therapeutic options and better clinical outcomes.Keywords
This publication has 60 references indexed in Scilit:
- B7-H3 as a promising target for cytotoxicity T cell in human cancer therapyOncotarget, 2016
- Breast Cancer Detection by B7-H3–Targeted Ultrasound Molecular ImagingCancer Research, 2015
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)The Lancet, 2015
- B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancerOncotarget, 2014
- Overexpression of B7-H3 in CD14+ monocytes is associated with renal cell carcinoma progressionMedical Oncology, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Proteome Profiling of Neuroblastoma-Derived Exosomes Reveal the Expression of Proteins Potentially Involved in Tumor ProgressionPLOS ONE, 2013
- Reversal of the TCR Stop Signal by CTLA-4Science, 2006
- Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR EngagementImmunity, 1996
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996